始めましょう
ReutersReuters

Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response

Refinitiv1分未満で読めます
RCUS

Arcus Biosciences Inc RCUS:

  • INITIAL DATA FROM THE ARC-20 STUDY OF CASDATIFAN PLUS CABOZANTINIB SHOWED NEARLY HALF OF PATIENTS WITH METASTATIC KIDNEY CANCER HAD A CONFIRMED RESPONSE

  • ARCUS BIOSCIENCES INC - ARC-20 STUDY SHOWS 46% RESPONSE RATE IN METASTATIC KIDNEY CANCER

Reuters
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう

Reutersからその他のニュース